Should I buy or sell Biora Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOR shares. View BIOR analyst ratings or view top-rated stocks .

How have BIOR shares performed in 2024?

Biora Therapeutics' stock was trading at $1.35 on January 1st, 2024. Since then, BIOR shares have decreased by 52.2% and is now trading at $0.6450. View the best growth stocks for 2024 here .

Are investors shorting Biora Therapeutics?

Biora Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,340,000 shares, an increase of 13.6% from the March 15th total of 1,180,000 shares. Based on an average daily volume of 464,400 shares, the short-interest ratio is currently 2.9 days. Currently, 4.2% of the shares of the company are sold short. View Biora Therapeutics' Short Interest .

When is Biora Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BIOR earnings forecast .

How were Biora Therapeutics' earnings last quarter?

Biora Therapeutics, Inc. (NASDAQ:BIOR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.01. The company earned $0.18 million during the quarter, compared to the consensus estimate of $11.10 million. During the same period in the previous year, the firm posted ($1.01) earnings per share.

When did Biora Therapeutics' stock split?

Shares of Biora Therapeutics reverse split before market open on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Biora Therapeutics?

Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BIOR

Biora Therapeutics (BIOR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free BIOR Stock Alerts

$0.64

+0.00 (+0.45%)

(As of 12:52 PM ET)

Compare

Today's Range: $0.63
▼
$0.68
50-Day Range: $0.62
▼
$1.54
52-Week Range: $0.61
▼
$6.70

Volume: 154,406 shs
Average Volume: 446,867 shs
Market Capitalization: $23.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Biora Therapeutics alerts:

Biora Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
4.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.68
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.46) to ($1.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

Medical Sector

853rd out of 914 stocks

Pharmaceutical Preparations Industry

390th out of 417 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Biora Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
4.16% of the float of Biora Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Biora Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biora Therapeutics has recently increased by 13.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biora Therapeutics does not currently pay a dividend.
Dividend Growth
Biora Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BIOR.

3.2

News and Social Media Coverage

News Sentiment
Biora Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 8 people have searched for BIOR on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
MarketBeat Follows
7 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biora Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.18% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biora Therapeutics are expected to grow in the coming year, from ($1.46) to ($1.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biora Therapeutics is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biora Therapeutics is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Biora Therapeutics Stock (NASDAQ:BIOR)

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

BIOR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIOR Stock News Headlines

April 18, 2024 | msn.com

Biora Therapeutics (BIOR) Price Target Decreased by 62.95% to 10.51

April 15, 2024 | nasdaq.com

Biora Therapeutics, Inc. Common Stock (BIOR)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | americanbankingnews.com

HC Wainwright Equities Analysts Boost Earnings Estimates for Biora Therapeutics, Inc. (NASDAQ:BIOR)

April 11, 2024 | americanbankingnews.com

Equities Analysts Issue Forecasts for Biora Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:BIOR)

April 10, 2024 | stockhouse.com

Biora Therapeutics Announces New Patent Covering its BioJet(TM) Liquid Jet Delivery Technology

April 10, 2024 | americanbankingnews.com

Biora Therapeutics (NASDAQ:BIOR) Trading Down 3.5%

April 9, 2024 | markets.businessinsider.com

Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 8, 2024 | globenewswire.com

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

April 4, 2024 | markets.businessinsider.com

Biora Therapeutics Gets Positive Interim Data From Clinical Trial Of BT-600 With NaviCap; Stock Down

April 4, 2024 | globenewswire.com

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

April 3, 2024 | globenewswire.com

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 2, 2024 | msn.com

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60%

April 1, 2024 | finance.yahoo.com

Biora Therapeutics Full Year 2023 Earnings: Beats Expectations

April 1, 2024 | msn.com

Precision Biosciences, Mesoblast, Pulse Biosciences among healthcare movers

April 1, 2024 | marketwatch.com

Biora Therapeutics Shares Drop 26% After Pricing of Direct Offering

April 1, 2024 | globenewswire.com

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 28, 2024 | seekingalpha.com

Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript

March 27, 2024 | finance.yahoo.com

BIOR: Negotiations Accelerating

March 27, 2024 | finance.yahoo.com

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript

March 27, 2024 | benzinga.com

Biora Therapeutics: Q4 Earnings Insights

March 27, 2024 | finanznachrichten.de

Biora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 27, 2024 | finance.yahoo.com

Q4 2023 Biora Therapeutics Inc Earnings Call

March 26, 2024 | globenewswire.com

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 25, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Biora Therapeutics's earnings

March 18, 2024 | globenewswire.com

Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

See More Headlines

Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BIOR
CUSIP: N/A
CIK: 1580063
Web: www.bioratherapeutics.com
Phone: 833-727-2841
Fax: N/A
Employees: 58
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($8.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-124,110,000.00
Net Margins: N/A
Pretax Margin: -3,110,600.00%
Return on Equity: N/A
Return on Assets: -147.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.30
Quick Ratio: 0.30

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.73) per share
Price / Book: -0.17

Miscellaneous

Outstanding Shares: 35,880,000
Free Float: 27,566,000
Market Cap: $23.04 million
Optionable: Optionable
Beta: 1.09

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Aditya P. Mohanty M.B.A. (Age 57)
CEO & Director
Comp: $984.14k
Mr. Eric d'Esparbes (Age 56)
Chief Financial Officer
Comp: $748.26k
Mr. Clarke Neumann J.D. (Age 60)
Senior VP, General Counsel & Secretary
Comp: $724.62k
Eric Fox
VP of Finance & Accounting & Treasurer
Mr. Troy Seelye (Age 60)
Chief Information Officer
Mr. George Gianakopoulos (Age 63)
Senior Vice President of Sales
Ms. Robyn Hatton
Head of Human Resources
Mr. Kevin Howe Ph.D.
Senior VP of Strategic Operations
Dr. Sharat Singh Ph.D. (Age 65)
Head of Research
Dr. Paul Shabram M.B.A.
Head of Technical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BIOR Stock Analysis - Frequently Asked Questions

Should I buy or sell Biora Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOR shares.
View BIOR analyst ratings or view top-rated stocks.
How have BIOR shares performed in 2024?: Biora Therapeutics' stock was trading at $1.35 on January 1st, 2024. Since then, BIOR shares have decreased by 52.2% and is now trading at $0.6450.
View the best growth stocks for 2024 here.
Are investors shorting Biora Therapeutics?: Biora Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,340,000 shares, an increase of 13.6% from the March 15th total of 1,180,000 shares. Based on an average daily volume of 464,400 shares, the short-interest ratio is currently 2.9 days. Currently, 4.2% of the shares of the company are sold short.
View Biora Therapeutics' Short Interest.
When is Biora Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our BIOR earnings forecast.

How were Biora Therapeutics' earnings last quarter?: Biora Therapeutics, Inc. (NASDAQ:BIOR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.01. The company earned $0.18 million during the quarter, compared to the consensus estimate of $11.10 million. During the same period in the previous year, the firm posted ($1.01) earnings per share.
When did Biora Therapeutics' stock split?: Shares of Biora Therapeutics reverse split before market open on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
How do I buy shares of Biora Therapeutics?: Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIOR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biora Therapeutics (BIOR) Stock Price, News & Analysis

Biora Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biora Therapeutics Stock (NASDAQ:BIOR)

BIOR Stock Price History

BIOR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

BIOR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™